HomeNewsCeva Animal Health opens Biogenovac Genomics Laboratory to develop future vaccines

Ceva Animal Health opens Biogenovac Genomics Laboratory to develop future vaccines

Ceva Animal Health has officially opened Biogenovac, a new genomics research laboratory in Beaucouzé, France. The facility, partially funded by the French government and the Pays de la Loire region, aims to advance vaccine development and combat emerging animal diseases.

The laboratory will focus on using high-throughput sequencing and bioinformatics to design and produce vaccines capable of addressing new and evolving infectious diseases. With these advanced technologies, Ceva aims to enhance vaccine effectiveness by tailoring solutions to the specific challenges faced in the field.

The company, which operates in 47 countries with 21 R&D centres, invests 10% of its annual turnover into research and development. The new platform aligns with Ceva’s One Health approach, which integrates animal, human, and environmental health.

Marc Prikazsky, Chairman and CEO of Ceva, emphasized that Biogenovac is a significant step in the company’s ability to innovate for the future of animal vaccination. He highlighted that this investment supports the development of customized solutions for emerging diseases and contributes to regional and industrial health sovereignty.

Ceva Animal Health is the fifth-largest animal health company globally, with over 7,000 employees and a 2023 turnover of €1.7 billion. The company focuses on preventive medicine, including vaccines and animal welfare products, for both farm and companion animals.

NEXT POSTS

Subscribe to our newsletter to get the latest news from industry

Newsletter Registration

DOWNLOAD OUR APP